Home › NDC Lookup › RxCUI directory › RxCUI 1044587

Tesamorelin 2 MG Injection — RxCUI 1044587

RxNorm drug concept · Semantic clinical drug
RxCUI 1044587 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1044587
Official nameTesamorelin 2 MG Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)287 prescriptions · 5 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tesamorelin Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Tesamorelin (EGRIFTA WR) is specifically designed to reduce the excess deep belly fat that can build up in HIV-positive people — a condition called lipodystrophy. It's not a genera...
  • What exactly is this medication supposed to do for me?
  • You'll inject it just under the skin of your abdomen once a day — that's called a subcutaneous injection. Before each injection, you mix the powder with the special liquid (diluent...
  • How do I give myself the injection, and does it hurt?
📖 Read our full Tesamorelin Injection guide →

🕸️ Concept Web — How Tesamorelin 2 MG Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Tesamorelin 2 MG Injection RxCUI 1044587

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Tesamorelin 1044584
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Egrifta 1044588
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Tesamorelin Injection 1719678
    • Tesamorelin Injectable Product 1161506
    • Tesamorelin Injection [Egrifta] 1719681
    • Egrifta Injectable Product 1173847
    • Injection 1649574
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Tesamorelin 2 MG SCDC · 1719677
  • Tesamorelin Injection SCDF · 1719678
  • Tesamorelin Injectable Product SCDG · 1161506

Brand-Name Concepts

  • Tesamorelin 2 MG Injection [Egrifta] SBD · 1044591
  • Tesamorelin 2 MG [Egrifta] SBDC · 1719680
  • Tesamorelin Injection [Egrifta] SBDF · 1719681
  • Egrifta Injectable Product SBDG · 1173847
  • Egrifta BN · 1044588

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1044587 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
62064-0241-30 1 KIT in 1 BOX (62064-241-30) * 30 BOTTLE in 1 TRAY / 10 m... EGRIFTA SV Theratechnologies Inc. 2019-11-04
Observed labelers: Theratechnologies Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.